A pilot study of cis-diamminedichloroplatinum and radiation therapy in patients with high grade astrocytomas

✍ Scribed by Lynn G. Feun; David J. Stewart; Moshe Maor; Milam Leavens; Niramol Savaraj; M. Andrew Burgess; Wai-Kwan A. Yung; Robert S. Benjamin

• Publisher: Springer US
• Year: 1983
• Tongue: English
• Weight: 310 KB
• Volume: 1
• Category: Article
• ISSN: 0167-594X
• DOI: 10.1007/bf00182955

✦ Synopsis

A pilot study was performed combining cis-diamminedichloroplatinum (CDDP) and radiation therapy to treat patients with high-grade astrocytomas. CDDP at a dose of 40 mg/m2/week intravenously was given during the course of cranial irradiation. Following irradiation, CDDP was given every three weeks on a schedule of 35 40 mg/m2/day for three days until toxicity became unacceptable or until tumor progression occurred. Radiation therapy consisted of 6 000 rads over a seven week period or 5 000 rads followed by an additional I 500 rads to the tumor site. Patients were followed by computerized axial tomography (CT) scan and neurologic examination. Thirty patients were entered onto the study; 22 were considered evaluable. The median survival was 53 weeks and the median time to progression was 21 weeks. Toxicity was generally tolerable; however, ototoxicity may be enhanced by this treatment. CDDP combined with cranial irradiation is tolerable and feasible, although close follow-up is recommended in case CDDP has to be temporarily interrupted.